keyword
MENU ▼
Read by QxMD icon Read
search

Intragam p

keyword
https://www.readbyqxmd.com/read/22212346/pharmacokinetics-and-safety-of-intragam-10-nf-the-next-generation-10-liquid-intravenous-immunoglobulin-in-patients-with-primary-antibody-deficiencies
#1
MULTICENTER STUDY
K Bleasel, R Heddle, P Hissaria, R Stirling, C Stone, D Maher
BACKGROUND AND AIMS: Intragam® 10 NF is the next generation 10% intravenous immunoglobulin with three pathogen reduction steps and a noncarbohydrate stabiliser. This open label, cross-over study in patients with primary immunodeficiency was designed to evaluate whether Intragam 10 NF differed in its pharmacokinetics (PK) compared with Intragam P and to assess Intragam 10 NF safety and tolerability. METHODS: Nineteen primary immunodeficiency patients were administered one cycle of their existing Intragam P dose (0...
March 2012: Internal Medicine Journal
https://www.readbyqxmd.com/read/19544484/evaluation-of-the-effect-of-intravenous-volume-expanders-upon-the-volume-of-distribution-of-gentamicin-in-septic-neonates
#2
Catherine M T Sherwin, Esther Kostan, Roland S Broadbent, Natalie J Medlicott, David M Reith
Sepsis has been reported to increase the volume of distribution of gentamicin in neonates. To determine whether this was caused by the use of intravenous volume expanders a retrospective nested case-control study was performed comparing confirmed septic neonates with non-septic controls. Data were collected on intravenous administration of 0.45% saline/10% dextrose, 0.45% saline/5% dextrose, 0.9% normal saline, red blood cells, platelets, immunoglobulin (Intragam P) and albumin. A population pharmacokinetic analysis was performed using NONMEM for 116 neonates (29 confirmed septic) from which 363 gentamicin serum concentrations were available...
July 2009: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/15030521/increased-risk-of-adverse-events-when-changing-intravenous-immunoglobulin-preparations
#3
R Ameratunga, J Sinclair, J Kolbe
Intravenous immunoglobulin (IVIG) therapy has represented a major advance in the treatment of patients with primary immune deficiency disorders. In September 2000 a new IVIG formulation, Intragam P, was introduced into clinical use. Intragam P is prepared by delipidation of pooled plasma followed by an ion exchange chromatography step to eliminate immunoglobulin aggregates. It is then pasteurized for 10 h at 60 degrees C for viral inactivation before storage at pH 4.25 in 10% maltose. We report initial clinical experience with this new preparation...
April 2004: Clinical and Experimental Immunology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"